Home » Authors » Brady Huggett

Articles by Brady Huggett

Invitrogen Prices $325M Worth Of Notes, Keeps Buying Power

July 30, 2003

By Brady Huggett

Invitrogen Prices $325M Worth Of Notes, Keeps Buying Power

July 30, 2003

By Brady Huggett

OxiGene Gets Orphan Status For CA4P; Stock Soars 50 Percent

July 29, 2003

By Brady Huggett

OxiGene Gets Orphan Status For CA4P; Stock Soars 50 Percent

July 29, 2003

By Brady Huggett

Antegren's Miss In Crohn's Mars Respectable Earnings For Biogen

July 25, 2003

By Brady Huggett

Biogen Inc. and partner Elan Corp. plc released disappointing Phase III data on Antegren in an induction trial in Crohn's disease, dragging both companies' stocks down and overshadowing positive second-quarter figures for Biogen. (BioWorld Today)

Antegren's Miss In Crohn's Mars Respectable Earnings For Biogen

July 25, 2003

By Brady Huggett

Biogen Inc. and partner Elan Corp. plc released disappointing Phase III data on Antegren in an induction trial in Crohn's disease, dragging both companies' stocks down and overshadowing positive second-quarter figures for Biogen. (BioWorld Today)

Diversa Acquiring GSK Antifungal Compounds For $8.6M In Equity

July 23, 2003

By Brady Huggett

Diversa Acquiring GSK Antifungal Compounds For $8.6M In Equity

July 23, 2003

By Brady Huggett

Medarex Raises $100M Via Notes Sale, Adds To Financing Flurry

July 21, 2003

By Brady Huggett

Medarex Raises $100M Via Notes Sale, Adds To Financing Flurry

July 21, 2003

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...